GURU.Markets stock price, segment price, and overall market index valuation
The company's share price DRUG
Shares of Bright Minds, a biotech company developing psychedelic drugs for the treatment of neurological disorders, are a highly speculative bet. Their price is driven not by financial performance, but by news of regulatory changes and early trial results.
Share prices of companies in the market segment - Pharma psycho
Bright Minds Biosciences is a biotechnology company developing a new generation of serotonergic drugs for the treatment of severe neurological and psychiatric disorders, such as epilepsy and depression. We have classified it in the "Pharma Psycho" segment. The chart below illustrates the overall dynamics in this complex yet socially significant pharmaceutical sector.
Broad Market Index - GURU.Markets
Bright Minds Biosciences is a biopharmaceutical company developing next-generation serotonin-based drugs for the treatment of psychiatric and neurological disorders. As a component of the GURU.Markets index, it represents the psychopharmacology sector. The chart below represents the entire market. See how Bright Minds shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
DRUG - Daily change in the company's share price DRUG
Change_co for Bright Minds, a biopharmaceutical company focused on psychedelics, reflects extreme volatility. Daily fluctuations indicate sensitivity to news about clinical trials and regulatory changes. This metric is important for analyzing speculative biotech companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma psycho
Bright Minds Biosciences Inc. is a biotech company working with psychedelics. This chart highlights the sector's extreme volatility. Comparing it to DRUG's performance helps assess it as a high-risk asset, dependent on clinical data and regulatory changes.
Daily change in the price of a broad market stock, index - GURU.Markets
Bright Minds is a biopharmaceutical company operating in the psychedelic medicine sector. This is a highly speculative and volatile sector. The chart below reflects average fluctuations in this niche, serving as an indicator of risks and investor expectations.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization DRUG
Bright Minds Biosciences' annual performance is a bet on developing a new generation of psychedelic drugs for the treatment of mental and neurological disorders. Its 12-month market cap depends on progress in preclinical research and investor confidence that its modified compounds will be safer and more effective than traditional psychedelics.
Annual dynamics of market capitalization of the market segment - Pharma psycho
Bright Minds Biosciences is a biotech company developing psychedelic drugs for the treatment of mental disorders. Its stock price is entirely speculative and based on investors' faith in the future potential of this innovative, yet controversial, approach to medicine.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Bright Minds, a biotech company researching psychedelics, is one of the most speculative stories on the market. Its stock price is completely unrelated to the economy. Its chart reflects the hopes, risks, and legislative changes surrounding one of the most controversial areas of medicine.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization DRUG
The valuation of Bright Minds, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of preclinical and clinical trials of its psychedelic-based drugs for the treatment of neurological disorders.
Monthly dynamics of market capitalization of the market segment - Pharma psycho
Bright Minds Biosciences is a biotech company developing next-generation psychedelic-based drugs for the treatment of mental and neurological disorders. This is a high-risk and hotly debated area. The biotech sector chart will reveal the overall interest in this niche, which is highly dependent on regulatory developments and clinical data.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Bright Minds Biosciences is developing next-generation drugs for the treatment of mental disorders. This is one of the most advanced and risky areas of biotech. The company's stock price is completely uncorrelated with the market, but rather reflects progress in clinical trials. The chart will show the ups and downs associated with scientific expectations.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization DRUG
Bright Minds Biosciences, a company developing psychedelic drugs for the treatment of neurological disorders, operates at the intersection of medicine and evolving legislation. Its weekly stock price reflects clinical data and news about the decriminalization and medical use of these substances.
Weekly dynamics of market capitalization of the market segment - Pharma psycho
Biotech companies researching psychedelics, like Bright Minds, are operating in a new and speculative market. The entire sector is driven by news of legalization and clinical trials. The chart below illustrates this general backdrop. It allows you to compare how Bright Minds' scientific approach appears more promising to investors than that of its competitors.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Bright Minds Biosciences is a biotech company developing next-generation psychedelic-inspired drugs for the treatment of mental disorders. The chart will show how volatile its shares are, living in their own speculative world, disconnected from the broader market.
Market capitalization of the company, segment and market as a whole
DRUG - Market capitalization of the company DRUG
Bright Minds Biosciences' market capitalization reflects investors' bets on a new generation of psychedelic drugs for treating mental disorders. The chart demonstrates the market's belief that its modified molecules will offer therapeutic benefits without the hallucinogenic side effects. Its value reflects the potential of this revolutionary approach to psychiatry.
DRUG - Share of the company's market capitalization DRUG within the market segment - Pharma psycho
Bright Minds Biosciences is developing next-generation psychedelic drugs for the treatment of mental and neurological disorders. In its niche market, its market capitalization reflects both its enormous hopes and its risks. The company's size reflects its bet that psychedelics will become a legal and effective part of modern medicine.
Market capitalization of the market segment - Pharma psycho
Below is a chart showing the total value of the entire pharmaceutical sector focused on treating mental disorders. For Bright Minds Biosciences, which works with next-generation psychedelics, this line is a map of a cultural and scientific revolution. Its growth demonstrates how investors are beginning to believe in the therapeutic potential of these once-banned substances.
Market capitalization of all companies included in a broad market index - GURU.Markets
Bright Minds Biosciences is developing a new generation of psychedelic drugs for the treatment of mental disorders. Its market capitalization is a bet on a medical revolution in psychiatry. This represents the share of the overall market occupied by scientific research into altered states of consciousness.
Book value capitalization of the company, segment and market as a whole
DRUG - Book value capitalization of the company DRUG
Bright Minds Biosciences is a biotechnology company developing next-generation drugs for the treatment of mental disorders. Its book value is the financial resources it has available for preclinical and clinical trials. How has this research capital changed? The chart below shows this trend.
DRUG - Share of the company's book capitalization DRUG within the market segment - Pharma psycho
Bright Minds Biosciences is developing next-generation psychedelic drugs. Its scientific work requires specialized resources: a laboratory for the synthesis and screening of new chemical compounds. The chart shows the company's share of the physical R&D infrastructure necessary for the creation of psychiatric drugs.
Market segment balance sheet capitalization - Pharma psycho
Bright Minds, a biopharmaceutical company developing psychedelics, has minimal physical assets. Its business is focused on R&D. The BCap_Seg chart for the biotech sector, which consists of hundreds of similar companies, is generally low, as the primary capital here is intellectual capital.
Book value of all companies included in the broad market index - GURU.Markets
Bright Minds' book value is its patent portfolio and preclinical research data on a new generation of psychedelic drugs for the treatment of mental disorders. The company's assets are capitalized science. The chart shows how this intangible asset is valued in this nascent industry.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - DRUG
Bright Minds' balance sheet is its R&D capital. Its entire market value is a premium on the hope that its new generation of psychedelic drugs will prove effective and safe for treating mental disorders. The schedule is a bet on the revival of this class of drugs.
Market to book capitalization ratio in a market segment - Pharma psycho
Bright Minds Biosciences is a company developing next-generation psychedelic drugs for the treatment of mental illness. Its valuation on this chart is a purely speculative bet on the future legalization and medical use of these substances.
Market to book capitalization ratio for the market as a whole
Bright Minds Biosciences is a biotech company developing psychedelic drugs for the treatment of neurological and psychiatric disorders. Its market valuation is based entirely on expectations of success in this new and promising area of medicine, creating a huge gap with its book value.
Debts of the company, segment and market as a whole
DRUG - Company debts DRUG
Bright Minds Biosciences, an early-stage company developing next-generation drugs for neuropsychiatric disorders, relies entirely on equity capital to fund its R&D. This chart shows the biotech startup's financial strategy, with all resources focused on preclinical research and scientific discovery.
Market segment debts - Pharma psycho
Bright Minds Biosciences is a biotech company developing next-generation drugs for the treatment of psychiatric and neurological disorders. At the preclinical stage, funding is entirely dependent on equity. This chart shows a debt-free environment, which is absolutely normal for companies at this stage of development.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio DRUG
Bright Minds Biosciences is a company developing psychedelic drugs for the treatment of neurological disorders. This is a new and risky field. This chart shows how reliant the company is on external funding for research. It reflects the very high level of speculative risk inherent in companies at the forefront of pharmaceutical innovation.
Market segment debt to market segment book capitalization - Pharma psycho
Bright Minds Biosciences is developing next-generation psychedelic drugs for the treatment of mental and neurological disorders. This is a resurgent but risky area of pharmacology. The chart shows how the biotech sector uses debt for R&D, providing context for assessing Bright Minds' financial strategy.
Debt to book value of all companies in the market
Bright Minds Biosciences is researching psychedelic compounds for the treatment of neurological disorders—a high-risk, high-potential area that requires funding. This chart shows the market's overall debt load, allowing one to assess how the company's financial strategy aligns with its position at the cutting edge of science, yet to be commercialized.
P/E of the company, segment and market as a whole
P/E - DRUG
Bright Minds Biosciences is a biotech company developing a new generation of psychedelic drugs for the treatment of severe mental and neurological disorders. This chart shows how investors view its scientific approach. This valuation depends on progress in clinical trials and changing attitudes toward psychedelic medicine.
P/E of the market segment - Pharma psycho
Bright Minds Biosciences develops psychedelic drugs. This chart shows the average valuation for the biotech sector. It emphasizes that Bright Minds is valued not by profit, but by the potential of its developments in this new and rapidly developing field of medicine, which carries both enormous opportunities and risks.
P/E of the market as a whole
Bright Minds Biosciences is developing a new generation of serotonergic drugs for the treatment of severe mental and neurological disorders, such as depression and epilepsy. This chart reflects the overall risk appetite of investors in biotech. It helps us understand whether DRUG's valuation is based on faith in the potential of its drugs or whether it moves in line with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company DRUG
Bright Minds Biosciences is a biotechnology company developing next-generation drugs for the treatment of psychiatric and neurological disorders. This chart reflects speculative market expectations regarding breakthroughs in the treatment of complex brain diseases and the commercial potential of its innovative molecules.
%20P%2FE%20DRUG&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-DRUG&v=1772539120411 "Chart of the company's future (projected) P/E DRUG")
Future (projected) P/E of the market segment - Pharma psycho
Bright Minds Biosciences is a biotech company developing next-generation psychedelic drugs for the treatment of mental and neurological disorders. The data here reflects the collective bet of analysts on the success of its research in this promising but risky field. It serves as a barometer of breakthrough expectations in psychopharmacology.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-psycho&v=1772539120552 "Future (projected) P/E graph of the market segment - Pharma psycho")
Future (projected) P/E of the market as a whole
Bright Minds Biosciences is developing next-generation psychedelic drugs for the treatment of mental and neurological disorders. This sentiment chart shows how willing investors are to embrace this new paradigm in medicine and fund companies working in this controversial but potentially groundbreaking field.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772539120594 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit DRUG
Bright Minds Biosciences is a company developing a new generation of psychedelic drugs for the treatment of neurological and psychiatric disorders. This chart shows the financial expenditures on research in this controversial but promising field. It reflects the investment in developing a therapy that could change the way depression is treated.
Profit of companies in the market segment - Pharma psycho
Bright Minds Biosciences is a biopharmaceutical company developing a new generation of drugs for the treatment of neuropsychiatric disorders. It operates in a complex yet socially significant field. Being in the early stages, its financial history is one of investing in science. Potential success could lead to treatment breakthroughs and significant profits.
Overall market profit
Bright Minds Biosciences is a biotech company developing a new generation of psychedelic drugs for the treatment of mental and neurological disorders. The need for such drugs is enormous, but success depends on clinical and regulatory results. This schedule, reflecting market conditions, impacts the company's ability to finance its long-term and risky projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company DRUG
Bright Minds Biosciences is a biotech company developing a new generation of serotonergic drugs for the treatment of psychiatric and neurological disorders. This chart shows analysts' speculative expectations. The forecast depends on the success of preclinical and clinical trials in a complex and highly competitive field.
%20profit%20of%20the%20company%20DRUG&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-DRUG&v=1772539120958 "Graph of future (projected) profit of the company DRUG")
Future (predicted) profit of companies in the market segment - Pharma psycho
Bright Minds Biosciences is a biotech company developing next-generation psychedelic-inspired drugs for the treatment of mental and neurological disorders. The pharmaceutical industry profitability projections shown on the chart provide a general overview. This chart helps assess the company's potential in this resurgent field of medicine.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-psycho&v=1772539121011 "Graph of future (predicted) profits of companies in a market segment - Pharma psycho")
Future (predicted) profit of the market as a whole
Bright Minds Biosciences is a company developing next-generation psychedelic drugs for the treatment of neurological and psychiatric disorders. This sector is in its early stages and is heavily dependent on venture capital funding and regulatory changes. The positive market backdrop, reflected in the chart, may increase investor interest in such innovative areas.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772539121063 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - DRUG
Bright Minds Biosciences is a biopharmaceutical company developing a new generation of psychedelic drugs for the treatment of mental and neurological disorders. It has no commercial revenue. This chart shows how investors view its potential in this resurgent and promising field of medicine.
P/S market segment - Pharma psycho
Bright Minds Biosciences is a biotechnology company developing a new generation of serotonergic drugs for the treatment of severe psychiatric and neurological disorders. This metric reflects the average revenue estimate for the sector and helps understand the market's perceived potential in innovative approaches to treating CNS disorders.
P/S of the market as a whole
Bright Minds Biosciences is a biotech company developing next-generation psychedelic drugs for the treatment of mental and neurological disorders. This chart provides context for understanding how investors value companies based on existing revenues, which is important when analyzing companies in the innovative but risky field of psychopharmacology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company DRUG
Bright Minds Biosciences is a biotech company developing next-generation psychedelic drugs for the treatment of neurological and psychiatric disorders. This chart reflects investor estimates of its potential future revenue. This valuation is a bet on the destigmatization and medical application of these substances.
%20P%2FS%20DRUG&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-DRUG&v=1772539121239 "The graph of the company's future (projected) P/S DRUG")
Future (projected) P/S of the market segment - Pharma psycho
Bright Minds Biosciences is a biotech company developing a new generation of psychedelic drugs for the treatment of mental and neurological disorders. This chart compares market expectations for its future revenue with other psychopharmaceutical companies. The valuation reflects investor confidence in the potential of this new class of drugs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-psycho&v=1772539121249 "Future (projected) P/S market segment graph - Pharma psycho")
Future (projected) P/S of the market as a whole
Bright Minds Biosciences is a biotech company developing a new generation of psychedelic drugs for the treatment of mental and neurological disorders. Its value lies in the potential of its research. This graph of overall market expectations is irrelevant for Bright Minds, as its future depends on changes in the regulatory environment and the success of its clinical programs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772539121307 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales DRUG
This chart shows the revenue of Bright Minds Biosciences, a company developing next-generation psychedelic-inspired drugs for the treatment of mental and neurological disorders. Being in the early clinical stage, the company has no commercial revenue. The chart emphasizes that its activities are entirely focused on research and development.
Sales of companies in the market segment - Pharma psycho
Bright Minds Biosciences is a biotechnology company developing a new generation of serotonergic drugs (psychedelics) for the treatment of severe mental and neurological disorders. This chart shows revenue in the psychopharmaceutical sector. It reflects the renewed interest in psychedelic medicine and its potential for creating breakthrough treatments for depression and other conditions.
Overall market sales
Bright Minds Biosciences is a biotechnology company developing next-generation drugs for the treatment of neuropsychiatric disorders. The demand for such drugs is high and independent of economic cycles. However, overall economic growth, reflected in this chart, affects the funding available for biotechnology R&D and healthcare budgets.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company DRUG
Bright Minds Biosciences is a biotech company at the forefront of psychedelic science, developing next-generation drugs for the treatment of mental disorders. This revenue projection is purely speculative. Its performance reflects analysts' confidence in the success of its preclinical and early clinical studies in this innovative field.
%20sales%20of%20the%20company%20DRUG&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-DRUG&v=1772539121591 "Schedule of future (projected) sales of the company DRUG")
Future (projected) sales of companies in the market segment - Pharma psycho
Bright Minds Biosciences is a biotech company developing a new generation of serotonin agonists for the treatment of severe mental and neurological disorders, such as depression and epilepsy. This chart shows projected revenues for the entire psychopharmaceutical sector, reflecting the search for more effective and safer brain drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-psycho&v=1772539121642 "Schedule of future (projected) sales of companies in the market segment - Pharma psycho")
Future (projected) sales of the market as a whole
Bright Minds Biosciences is a biotechnology company developing next-generation drugs for the treatment of neurological and psychiatric disorders. Its success depends on scientific breakthroughs. The overall economic climate influences investor willingness to fund such cutting-edge, yet risky, psychopharmacological research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772539121667 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality DRUG
Bright Minds Biosciences is a biotech company developing next-generation drugs for the treatment of neuropsychiatric disorders. Currently in the preclinical stage, it is entirely focused on R&D. This chart reflects its investment in research, showing the costs of creating drugs that could help millions of people.
Market segment marginality - Pharma psycho
Bright Minds Biosciences is a biotech company developing a new generation of serotonergic drugs for the treatment of psychiatric and neurological disorders. This chart reflects its operating efficiency. For a preclinical company, profitability is not a key metric, but it does demonstrate the effectiveness of managing initial costs.
Market marginality as a whole
Bright Minds Biosciences is a biotech company developing a new generation of psychedelic drugs for the treatment of neurological and psychiatric disorders. The need for such drugs is enormous and is not dependent on the economic situation, as reflected in this chart. The company's success depends on the results of clinical trials and changes in the regulatory environment.
Employees in the company, segment and market as a whole
Number of employees in the company DRUG
Bright Minds Biosciences is a biotech company developing a new generation of psychedelic drugs for the treatment of neurological and psychiatric disorders. This graph shows a small team of scientists. A small staff is typical for an early-stage company focused on preclinical research.
Share of the company's employees DRUG within the market segment - Pharma psycho
Bright Minds Biosciences is a biotech company researching next-generation psychedelics for the treatment of mental disorders. Being in the early stages, it operates with a very small team of scientists. This chart illustrates its status: its minimal staff reflects its focus on preclinical research and the search for breakthrough molecules.
Number of employees in the market segment - Pharma psycho
Bright Minds Biosciences is a biotech company developing a new generation of psychedelic drugs for the treatment of mental and neurological disorders. This chart reflects the renewed interest in this class of drugs. A small team of scientists is working on creating compounds that retain therapeutic effects but lack hallucinogenic properties.
Number of employees in the market as a whole
Bright Minds Biosciences is a biotechnology company developing a new generation of drugs for the treatment of psychiatric and neurological disorders. Its staff consists of neurobiologists and chemists. This employment chart highlights that in advanced pharmaceuticals, hiring is driven by scientific progress and clinical program needs, not by general economic trends.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company DRUG (DRUG)
Bright Minds Biosciences is a biotech company developing a new generation of psychedelic drugs for the treatment of mental and neurological disorders. This chart shows a very high cost per employee. The market is betting that the company's scientific research will lead to breakthrough treatments and is valuing its intellectual capital.
%20of%20the%20company%20DRUG%20(DRUG)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-DRUG-DRUG&v=1772539122064 "Chart of market capitalization per employee (in thousands of dollars) of the company DRUG (DRUG)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma psycho
Bright Minds Biosciences is developing next-generation psychedelic drugs for the treatment of mental disorders. In this innovative and sensitive field, this chart reflects market expectations. The high market capitalization per employee suggests that investors see great potential in their research, led by a small but highly qualified team.
%20by%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-psycho&v=1772539122081 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma psycho")
Market capitalization per employee (in thousands of dollars) for the overall market
Bright Minds Biosciences is a biopharmaceutical company developing next-generation psychedelic drugs. This metric reflects a business in a controversial but potentially disruptive field. Its market capitalization is based on the prospects for legalization and clinical application of its developments. A small team of scientists works at the forefront of neuroscience.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772539122115 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company DRUG (DRUG)
Bright Minds Biosciences is a preclinical biotech company developing a new generation of psychedelics for the treatment of neurological disorders. They are not profitable. This chart shows the loss per employee. This is the cost of running a small team of chemists and pharmacologists at the very early stages of drug development.
%20Chart%20DRUG%20(DRUG)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-DRUG-DRUG&v=1772539122173 "Company Profit Per Employee (in thousands of dollars) Chart DRUG (DRUG)")
Profit per employee (in thousands of dollars) in the market segment - Pharma psycho
Bright Minds Biosciences is a preclinical biotech company developing a new generation of psychedelic-inspired drugs for mental disorders. "Profit" here is the negative number (R&D expenses). This metric reflects the costs of their small team in the very early stages of drug development.
%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-psycho&v=1772539122186 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma psycho")
Profit per employee (in thousands of dollars) for the market as a whole
Bright Minds Biosciences is a biotech company researching psychedelics and serotonin agonists for the treatment of mental disorders. They are in the early, preclinical stage. This graph shows the "cost of science"—a negative value reflecting the investment spent on each scientist researching and developing the next generation of neurotherapeutics.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772539122226 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee DRUG (DRUG)
Bright Minds Biosciences is a biotech company developing a new generation of psychedelic drugs for the treatment of neurological and psychiatric disorders. This schedule is typical for an early-stage company. The lack of revenue per employee means all resources are focused on preclinical research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-DRUG-DRUG&v=1772539122364 "Sales chart per company employee DRUG (DRUG)")
Sales per employee in the market segment - Pharma psycho
Bright Minds (DRUG) is a biotech company developing a new generation of psychedelic-based drugs (but without the hallucinogenic effects) for the treatment of neurological and mental disorders. This chart shows the revenue (if any) generated by each employee (scientist). It's an indicator of the productivity of their R&D platform in this innovative but complex niche.
Sales per employee for the market as a whole
Bright Minds Biosciences is a biotech company developing a new generation of psychedelic drugs for the treatment of mental and neurological disorders. It is an early-stage (preclinical) R&D company. The company has no revenue, and its revenue is close to zero.
Short shares by company, segment and market as a whole
Shares shorted by company DRUG (DRUG)
Bright Minds Biosciences is a biotech company developing psychedelic-based drugs for the treatment of neurological disorders. This chart shows bearish bets. The bears are betting on high regulatory hurdles (the fight against the DEA) and the risk that trials will not prove the effectiveness of these controversial compounds.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-DRUG-DRUG&v=1772539122810 "Short Shares Chart for the Company DRUG (DRUG)")
Shares shorted by market segment - Pharma psycho
Bright Minds Biosciences is a biotech company developing a new generation of psychedelic drugs for the treatment of depression and other disorders. This chart shows skepticism. The "shorts" here are bets that their drugs will fail clinical trials or that regulators will not approve psychedelics.
Shares shorted by the overall market
Bright Minds Biosciences is a biotech company researching psychedelics (such as LSD analogs) for the treatment of neurological and psychiatric disorders. This is a highly speculative field. This chart illustrates the general market fear. When investors panic, they dump the riskiest and most hyped assets first, and the psychedelics sector is one of them.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator DRUG (DRUG)
Bright Minds Biosciences develops psychedelics for the treatment of neurological disorders. The stock is highly speculative. This chart can soar above 70 on positive R&D news or hype. The <30 zone often reflects setbacks, regulatory barriers, or risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-DRUG-DRUG&v=1772539123153 "RSI 14 indicator chart for the company's stock DRUG (DRUG)")
RSI 14 Market Segment - Pharma psycho
Bright Minds (DRUG) is a pioneer in psychedelics. They're developing a *new generation* of (non-hallucinogenic?) psychedelics for the treatment of mental disorders. The RSI_14_Seg for "Pharma psycho" (biotech) shows the overall sentiment. The chart helps us understand: is DRUG's volatility just hype, or is the entire sector overheated?
RSI 14 for the overall market
Bright Minds (DRUG) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast DRUG (DRUG)
Bright Minds (DRUG) is a biotech company developing next-generation psychedelic and serotonergic drugs for the treatment of mental disorders. This chart shows the average 12-month forecast, reflecting analysts' speculative assessment of this emerging area of pharmaceuticals.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-DRUG-DRUG&v=1772539123345 "A chart showing analyst consensus forecasts for the expected stock price. DRUG (DRUG)")
The difference between the consensus estimate and the actual stock price DRUG (DRUG)
Bright Minds is an early-stage biotech company working in the speculative field of psychedelics. They are developing a new generation of drugs (serotonin analogs) aimed at treating severe epilepsy and mental disorders. This graph reflects analysts' hypothetical expectations for their preclinical R&D program.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-DRUG-DRUG&v=1772539123351 "A chart showing the difference between the consensus forecast and the actual stock price. DRUG (DRUG)")
Analyst consensus forecast for stock prices by market segment - Pharma psycho
Bright Minds Biosciences is a biotech company developing a new generation of psychedelics (LSD and psilocybin analogs) for the treatment of mental disorders. This chart shows general expectations for the psychopharmacology sector. It reflects whether experts believe in the legalization and medical use of psychedelics.
Analysts' consensus forecast for the overall market share price
Bright Minds Biosciences (DRUG) is a biopharmaceutical company working at the forefront of psychiatry. They are developing a new generation of "safe" psychedelic drugs for the treatment of depression and PTSD. This chart shows the overall risk appetite, reflecting the market's willingness to fund breakthrough but regulatory-challenging areas of medicine.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index DRUG
Bright Minds is a preclinical biotech company working in the field of psychedelic medicine. They are developing a new generation of psychedelics (non-hallucinatory) for the treatment of epilepsy and depression. This graph represents pure R&D betting, likely reflecting the market's confidence in their chemistry platform and early lab data.
AKIMA Market Segment Index - Pharma psycho
Bright Minds (DRUG) is a clinical-stage biotech focused on psychedelics; the company (like MindMed) is developing a new generation of (non-hallucinogenic) psychedelic-based drugs for the treatment of depression. This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this futuristic (R&D) bet (DRUG) differentiate it from the average pharma company?
The AKIM Index for the overall market
Bright Minds Biosciences is a biotech company developing a new generation of serotonin receptor-targeted drugs (psychedelics 2.0) for brain treatment. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative story in the "neuro" sector fits within the context of overall economic trends.
